Compare
Onconetix, Inc. vs Lexaria Bioscience Corp. vs 60 Degrees Pharmaceuticals, Inc. vs Polomar Health Services, Inc.
| Latest fiscal year | Onconetix, Inc. ONCO | Lexaria Bioscience Corp. LEXX | 60 Degrees Pharmaceuticals, Inc. SXTP | Polomar Health Services, Inc. PMHS |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-08-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $815.4K | $705.9K | $1.01M | $648.2K |
| Revenue growth (YoY) | -67.7% | +52.0% | +65.5% | n/m |
| Gross margin | 77.6% | 99.6% | 22.3% | 71.0% |
| Operating margin | n/m | n/m | -771.6% | n/m |
| Net margin | n/m | n/m | -732.5% | n/m |
| Net income | -$14.03M | -$11.90M | -$7.37M | -$10.70M |
| EPS (Diluted) | -$16.56 | -$0.66 | -$11.73 | -$0.39 |
| Operating cash flow | -$9.68M | -$10.45M | -$6.85M | -$396.0K |
| Free cash flow | n/a | -$10.48M | -$6.99M | n/a |
| Cash & equivalents | n/a | n/a | $1.51M | $132.2K |
| Total assets | $24.93M | $4.18M | $5.37M | $390.0K |
| Total liabilities | $9.16M | $1.57M | $1.99M | $1.61M |
| Shareholders' equity | $15.76M | $2.99M | $3.46M | -$1.22M |
| Return on year-end equity | -89.0% | -398.1% | -212.7% | n/a |
| Shares outstanding | 1.56M | 19.56M | 1.16M | 28.02M |
Revenue, most recent five fiscal years
| Fiscal year | Onconetix, Inc. | Lexaria Bioscience Corp. | 60 Degrees Pharmaceuticals, Inc. | Polomar Health Services, Inc. |
|---|---|---|---|---|
| Latest | $815.4K Ended 2025-12-31 | $705.9K Ended 2025-08-31 | $1.01M Ended 2025-12-31 | $648.2K Ended 2025-12-31 |
| 1 year earlier | $2.52M Ended 2024-12-31 | $464.3K Ended 2024-08-31 | $607.6K Ended 2024-12-31 | $58.8K Ended 2024-12-31 |
| 2 years earlier | $58.5K Ended 2023-12-31 | $226.2K Ended 2023-08-31 | $253.6K Ended 2023-12-31 | $41.8K Ended 2023-12-31 |
| 3 years earlier | n/a | $255.4K Ended 2022-08-31 | $223.2K Ended 2022-12-31 | $34.5K Ended 2022-12-31 |
| 4 years earlier | n/a | $722.7K Ended 2021-08-31 | n/a | n/a |